A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

This study is testing a new form of blinatumomab — a drug that helps immune cells find and destroy cancer cells — given as a subcutaneous (under-the-skin) injection rather than intravenously, in children with relapsed or treatment-resistant B-cell acute lymphoblastic leukemia (B-ALL), a type of childhood blood cancer. **You may be eligible if...** - Your child is between 28 days old and under 12 years old - Your child has B-cell acute lymphoblastic leukemia (B-ALL) that has come back or stopped responding to treatment - Your child is reasonably active and functional - Prior CD19-targeted therapy (like certain CAR-T treatments) is allowed if the cancer still has CD19 markers and treatment has ended at least 30 days ago - For MRD-positive B-ALL: your child has a low but detectable level of leukemia cells in the bone marrow **You may NOT be eligible if...** - Your child is 12 or older - Your child has active CNS (brain/spinal fluid) involvement by leukemia - Your child has had a recent stem cell transplant without adequate recovery time Talk to your doctor to see if this trial is right for you.